165 related articles for article (PubMed ID: 38609396)
21. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation.
Jentzsch M; Bischof L; Ussmann J; Backhaus D; Brauer D; Metzeler KH; Merz M; Vucinic V; Franke GN; Herling M; Platzbecker U; Schwind S
Blood Cancer J; 2022 Dec; 12(12):170. PubMed ID: 36529759
[TBL] [Abstract][Full Text] [Related]
22. Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study.
Datoguia TS; Velloso EDRP; Helman R; Musacchio JG; Salvino MA; Soares RA; Higashi M; Fadel AV; E Silva RSA; Hamerschlak N; Santos FPS; Campregher PV
Med Oncol; 2018 Sep; 35(11):141. PubMed ID: 30187210
[TBL] [Abstract][Full Text] [Related]
23. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
[No Abstract] [Full Text] [Related]
25. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
Eisfeld AK; Kohlschmidt J; Mims A; Nicolet D; Walker CJ; Blachly JS; Carroll AJ; Papaioannou D; Kolitz JE; Powell BE; Stone RM; de la Chapelle A; Byrd JC; Mrózek K; Bloomfield CD
Leukemia; 2020 Dec; 34(12):3215-3227. PubMed ID: 32461631
[TBL] [Abstract][Full Text] [Related]
26. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.
Fenwarth L; Thomas X; de Botton S; Duployez N; Bourhis JH; Lesieur A; Fortin G; Meslin PA; Yakoub-Agha I; Sujobert P; Dumas PY; Récher C; Lebon D; Berthon C; Michallet M; Pigneux A; Nguyen S; Chantepie S; Vey N; Raffoux E; Celli-Lebras K; Gardin C; Lambert J; Malfuson JV; Caillot D; Maury S; Ducourneau B; Turlure P; Lemasle E; Pautas C; Chevret S; Terré C; Boissel N; Socié G; Dombret H; Preudhomme C; Itzykson R
Blood; 2021 Jan; 137(4):524-532. PubMed ID: 32871585
[TBL] [Abstract][Full Text] [Related]
27. Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.
Chen E; Jiao C; Yu J; Gong Y; Jin D; Ma X; Cui J; Wu Z; Zhou J; Wang H; Su B; Ge J
Cancer Med; 2023 Dec; 12(24):21615-21626. PubMed ID: 38098254
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.
Zhai Y; Wang Q; Ji L; Ren H; Dong Y; Yang F; Yin Y; Liang Z; Wang Q; Liu W; Mei Y; Zhang L; Li Y
Cancer Med; 2023 Dec; 12(24):21592-21604. PubMed ID: 38062912
[TBL] [Abstract][Full Text] [Related]
29. The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients.
Wang X; Wang J; Wei S; Zhao J; Xin B; Li G; Zhao J; Wu D; Luo M; Zhao S; Chen Y; Liu H; Zhang H; Wang J; Wang W; Wang H; Xiong H; He P
Front Med (Lausanne); 2023; 10():1165445. PubMed ID: 37435533
[TBL] [Abstract][Full Text] [Related]
30. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
31. Real-world genomic profiling of acute myeloid leukemia and the impact of European LeukemiaNet risk stratification 2022 update.
da Rosa SEA; de Lima LB; Silveira CN; Cortes LGF; de Oliveira Filho JB; de Souza Reis R; Cervato MC; Rodrigues PHS; de Oliveira Pelegrino K; Petroni RC; da Silva Araujo E; Campregher PV
Clin Transl Oncol; 2023 Dec; 25(12):3431-3436. PubMed ID: 37165281
[TBL] [Abstract][Full Text] [Related]
32. Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Harada K; Konuma T; Machida S; Mori J; Aoki J; Uchida N; Ohashi K; Fukuda T; Tanaka M; Ikegame K; Ozawa Y; Iwato K; Eto T; Onizuka M; Ichinohe T; Atsuta Y; Yano S
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1730-1743. PubMed ID: 31054982
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a promising 5-gene prognostic model for pediatric acute myeloid leukemia.
Tao Y; Wei L; Shiba N; Tomizawa D; Hayashi Y; Ogawa S; Chen L; You H
Mol Biomed; 2024 Jan; 5(1):1. PubMed ID: 38163849
[TBL] [Abstract][Full Text] [Related]
34. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
Reville PK; Sasaki K; Kantarjian HM; Daver NG; Yilmaz M; Dinardo CD; Short NJ; Borthakur G; Pemmaraju N; Mehta RS; Pierce S; Konoplev SN; Khoury JD; Garcia-Manero G; Konopleva MY; Jabbour E; Ravandi F; Kadia TM
Am J Hematol; 2022 Mar; 97(3):329-337. PubMed ID: 34981570
[TBL] [Abstract][Full Text] [Related]
35. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation.
Kongtim P; Hasan O; Perez JMR; Varma A; Wang SA; Patel KP; Chen J; Rondon G; Srour S; Bashir Q; Qazilbash M; Mehta R; Shpall EJ; Alousi A; Khouri I; Kebriaei P; Popat U; Champlin RR; Ciurea SO
Biol Blood Marrow Transplant; 2020 Jan; 26(1):197-203. PubMed ID: 31518645
[TBL] [Abstract][Full Text] [Related]
36. Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.
Falini B; Dillon R
Blood Cancer Discov; 2024 Jan; 5(1):8-20. PubMed ID: 37917833
[TBL] [Abstract][Full Text] [Related]
37. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
Jimenez Jimenez AM; De Lima M; Komanduri KV; Wang TP; Zhang MJ; Chen K; Abdel-Azim H; Abid MB; Aljurf M; Alkhateeb H; Assal A; Bacher U; Baron F; Battiwalla M; Beitinjaneh A; Bejanyan N; Bhatt VR; Byrne M; Cahn JY; Cairo M; Castillo P; Copelan E; DeFilipp Z; Perez MAD; Elsawy M; Gale RP; George B; Grunwald MR; Hildebrandt GC; Hogan WJ; Kanakry CG; Kansagra A; Kharfan-Dabaja MA; Khera N; Krem MM; Lazaryan A; Maakaron J; Martino R; McGuirk J; Michelis FV; Milone G; Mishra A; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Palmisiano N; Patel S; Saad A; Seo S; Sharma A; Solh M; Verdonck LF; Wirk B; Yared JA; Litzow M; Kebriaei P; Hourigan CS; Saber W; Weisdorf D
Bone Marrow Transplant; 2021 Dec; 56(12):3068-3077. PubMed ID: 34584240
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetic abnormalities in
Fu W; Huang A; Xu L; Peng Y; Gao L; Chen L; Chen J; Tang G; Yang J; Ni X
Leuk Lymphoma; 2022 Aug; 63(8):1956-1963. PubMed ID: 35227153
[No Abstract] [Full Text] [Related]
39. TG-interacting factor 1 improves risk stratification in patients with NPM1-mutated acute myeloid leukemia.
Tang H; Zhang N; Li H; Chen Y; Liu X; Xiao H; Deng J; Zhou K
Adv Clin Exp Med; 2023 Jul; 32(7):741-751. PubMed ID: 36753372
[TBL] [Abstract][Full Text] [Related]
40. Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia.
Calleja A; Loschi M; Bailly L; Morisot A; Marceau A; Mannone L; Robert G; Auberger P; Preudhomme C; Raynaud S; Subtil F; Sujobert P; Cluzeau T
Cancer Med; 2023 Mar; 12(5):5656-5660. PubMed ID: 36394159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
